Log in to your Inderes Free account to see all free content on this page.
EQL Pharma
54.60 SEK
+0.74 %
Less than 1K followers
EQL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for EQL Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 50.0 | 72.0 | 179.1 | 409.8 | 259.9 | 264.2 | 373.5 |
| growth-% | 44.1 % | 148.7 % | 128.7 % | -36.6 % | 1.6 % | 41.4 % | |
| EBITDA | 3.4 | 7.3 | 11.4 | 38.8 | 41.3 | 32.6 | 67.4 |
| EBIT | -1.4 | 3.2 | 11.4 | 38.8 | 41.3 | 32.6 | 67.4 |
| Profit before taxes | -1.5 | 2.7 | 10.4 | 36.0 | 39.0 | 28.6 | 54.4 |
| Net income | -1.5 | 2.7 | 10.4 | 31.6 | 30.9 | 22.7 | 43.1 |
| EPS | -0.05 | 0.09 | 0.36 | 1.09 | 1.09 | 0.78 | 1.48 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 6.8 % | 10.1 % | 6.4 % | 9.5 % | 15.9 % | 12.3 % | 18.0 % |
| EBIT-% | -2.8 % | 4.4 % | 6.4 % | 9.5 % | 15.9 % | 12.3 % | 18.0 % |
| ROE | -1.9 % | 3.3 % | 11.4 % | 25.5 % | 20.0 % | 12.8 % | 19.5 % |
| ROI | -1.5 % | 2.2 % | 5.2 % | 13.3 % | 10.8 % | 6.1 % | 5.3 % |
Login required
This content is only available for logged in users